Fecal occult blood testing when colonoscopy capacity is limited

Journal of the National Cancer Institute

Volumn 103, Issue 23, 2011, Pages 1741-1751

  Wilschut, Janneke A ^a   Habbema, J Dik F ^a   Van Leerdam, Monique E ^a   Hol, Lieke ^a   Lansdorp Vogelaar, Iris ^a   Kuipers, Ernst J ^a   Van Ballegooijen, Marjolein ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ADENOMA; ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COLONOSCOPY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FECAL IMMUNOCHEMICAL TEST; FECAL OCCULT BLOOD TESTING; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; OCCULT BLOOD TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; COLONOSCOPY; COLORECTAL NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); COST-BENEFIT ANALYSIS; FEMALE; GUAIAC; HEMOGLOBINS; HUMANS; IMMUNOCHEMISTRY; INDICATORS AND REAGENTS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY;

EID: 83255176965     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr385     Document Type: Article

References (43)

1. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472-1477. (Pubitemid 26400242)
2. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467-1471. (Pubitemid 26400241)
3. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91(5):434-437. (Pubitemid 29128279)
4. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59(1):62-68.
5. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer. 2009;100(7):1103-1110.
6. Van Rossum LG, van Rijn AF, Laheij RJ, et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer. 2009;101(8):1274-1281.
7. Van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135(1):82-90. (Pubitemid 351899018)
8. Canard JM, Debette-Gratien M, Dumas R, et al. A prospective national study on colonoscopy and sigmoidoscopy in 2000 in France. Gastroenterol Clin Biol. 2005;29(1):17-22. (Pubitemid 40254644)
9. Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J. Option appraisal of population-based colorectal cancer screening programmes in England. Gut. 2007;56(5):677-684. (Pubitemid 46662935)
10. Terhaar sive Droste JS, Craanen ME, Kolkman JJ, Mulder CJ. Dutch endoscopic capacity in the era of colorectal cancer screening. Neth J Med. 2006;64(10):371-373. (Pubitemid 44811214)
11. Kanavos P, Schurer W. The dynamics of colorectal cancer management in 17 countries. Eur J Health Econ. 2010;10(suppl 1):S115-S129.
12. Canadian Task Force on Preventive Health C. Colorectal cancer screening. Recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ. 2001;165(2):206-208.
13. Malila N, Anttila A, Hakama M. Colorectal cancer screening in Finland: details of the national screening programme implemented in Autumn 2004. J Med Screen. 2005;12(1):28-32. (Pubitemid 40445073)
14. Parkin DM, Tappenden P, Olsen AH, Patnick J, Sasieni P. Predicting the impact of the screening programme for colorectal cancer in the UK. J Med Screen. 2008;15(4):163-174.
15. Loeve F, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JD. Final Report MISCAN-COLON Microsimulation Model for Colorectal Cancer: Report to the National Cancer Institute Project No. NO1-CN55186. Rotterdam, the Netherlands: Department of Public Health, Erasmus University; 1998.
16. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res. 1999;32(1):13-33. (Pubitemid 29102594)
17. Vogelaar I, van Ballegooijen M, Zauber AG, et al. Model Profiler of the MISCAN-Colon Microsimulation Model for Colorectal Cancer. Rotterdam, the Netherlands: Department of Public Health, Erasmus MC; 2004. https://cisnet. flexkb.net/mp/pub/cisnet-colorectal-sloankettering-profile.pdf.
18. Lemmens V, van Steenbergen L, Janssen-Heijnen M, Martijn H, Rutten H, Coebergh JW. Trends in colorectal cancer in the south of the Netherlands 1975-2007: rectal cancer survival levels with colon cancer survival. Acta Oncol. 2010;49(6):784-796.
19. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD. A novel hypothesis on the sensitivity of the fecal occult blood test: results of a joint analysis of 3 randomized controlled trials. Cancer. 2009;115(11):2410- 2419.
20. Loeve F, Boer R, Zauber AG, et al. National Polyp Study data: evidence for regression of adenomas. Int J Cancer. 2004;111(4):633-639. (Pubitemid 39045333)
21. Vogelaar I, van Ballegooijen M, Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the U.S? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer. 2006;107(7):1624-1633. (Pubitemid 44546924)
22. Van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006;101(2):343-350. (Pubitemid 43381678)
23. Nagengast FM, Kaandorp CJ. [Revised CBO guideline 'Follow-up after polypectomy']. Ned Tijdschr Geneeskd. 2001;145(42):2022-2025. (Pubitemid 32979472)
24. Colquhoun P, Chen HC, Kim JI, et al. High compliance rates observed for follow up colonoscopy post polypectomy are achievable outside of clinical trials: efficacy of polypectomy is not reduced by low compliance for follow up. Colorectal Dis. 2004;6(3):158-161. (Pubitemid 38660634)
25. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328(19):1365-1371. (Pubitemid 23131388)
26. Weller D, Coleman D, Robertson R, et al. The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer. 2007;97(12):1601-1605. (Pubitemid 350249359)
27. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol. 1999;94(6):1650-1657. (Pubitemid 29260460)
28. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88(6):1294-1303. (Pubitemid 30155164)
29. Zorzi M, Barca A, Falcini F, et al. Screening for colorectal cancer in Italy: 2005 survey. Epidemiol Prev. 2007;31(2-3) (suppl 2):49-60.
30. De Kok IM, Polder JJ, Habbema JD, et al. The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening. Br J Cancer. 2009;100(8):1240-1244.
31. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst. 2009;101(20):1412-1422.
32. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630-641.
33. Flanagan WM, Le Petit C, Berthelot JM, White KJ, Coombs BA, Jones-McLean E. Potential impact of population-based colorectal cancer screening in Canada. Chronic Dis Can. 2003;24(4):81-88. (Pubitemid 38155545)
34. Lau A, Gregor JC. Resource implications for a population-based colorectal cancer screening program in Canada: a study of the impact on colonoscopy capacity and costs in London, Ontario. Can J Gastroenterol. 2007;21(6):371-377. (Pubitemid 47177085)
35. Nnoaham KE, Lines C. Modelling future capacity needs and spending on colonoscopy in the English bowel cancer screening programme. Gut. 2008;57(9):1238-1245.
36. Rodriguez-Moranta F, Trapero-Bertran M, Castells A, et al. Endoscopic requirements of colorectal cancer screening programs in average-risk population. Estimation according to a Markov model. Gastroenterol Hepatol. 2008;31(7):405-412.
37. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334(3):155-159. (Pubitemid 26017953)
38. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624-1633.
39. Brown ML, Klabunde CN, Mysliwiec P. Current capacity for endoscopic colorectal cancer screening in the United States: data from the National Cancer Institute Survey of Colorectal Cancer Screening Practices. Am J Med. 2003;115(2):129-133. (Pubitemid 37288841)
40. Campo R, Brullet E, Junquera F, et al. [Sedation in digestive endoscopy. Results of a hospital survey in Catalonia (Spain)] Sedacion en la endoscopia digestiva. Resultados de una encuesta hospitalaria en Cataluna. Gastroenterol Hepatol. 2004;27(9):503-507. (Pubitemid 39587091)
41. Seeff LC, Richards TB, Shapiro JA, et al. How many endoscopies are performed for colorectal cancer screening? Results from CDC's survey of endoscopic capacity. Gastroenterology. 2004;127(6):1670-1677. (Pubitemid 39575845)
42. Vijan S, Inadomi J, Hayward RA, Hofer TP, Fendrick AM. Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the United States. Aliment Pharmacol Ther. 2004;20(5):507-515. (Pubitemid 39243896)
43. Macrae FA. Providing colonoscopy services for the National Bowel Cancer Screening Program. Med J Aust. 2007;186(6):280-281.